JNJ

Looking for a Pullback to Pick Up Johnson & Johnson’s Shares

by

This article appeared on Seeking Alpha. Please view disclosures: https://seekingalpha.com/article/278789-looking-for-a-pullback-to-pick-up-johnson-and-johnsons-shares As long-time followers of Johnson & Johnson (click ticker for report: ) know, the firm is a steady, established company that has pursued somewhat of a defensive strategy in light of the global economic situation, which continues to muddle along in the US. J&J has pulled back on capital expenditures and R&D, while cutting overhead expenses, amounting to material operating savings. Operating margins have improved from about 26.6% in 2008 to over 27.5% in 2010, and we think there is further room for expansion in coming years. We believe these operating improvements to be a low risk measure to improve the bottom line, and with expansion into international markets, the firm should … Read more

Earnings Roundup for the Week Ended Sunday, April 19, Covering Companies Across the Board

by

By Callum Turcan Let’s take a look at several earnings reports across numerous industries in this article as the ongoing coronavirus (‘COVID-19’) pandemic forces the global economy to a crawl. Please note that as these reports primarily cover the first quarter of calendar year 2020, the impact of the pandemic has yet to be truly reflected in corporate earnings. That said, these reports still provide an important glimpse into what to expect going forward and how companies are responding to the pandemic. By ticker in alphabetical order: BBBY, CPSS, ISRG, LAKE, MRTN, OFLX, SCHW, TSM Bed Bath & Beyond Inc (BBBY) Shares of BBBY shot up on April 16 after reporting fourth quarter and full-year results for its fiscal 2019 … Read more

Nelson: The 16 Most Important Steps To Understand The Stock Market

by

A previous version of this article appeared on our website July 21, 2013. Refreshed and updated throughout, as of July 2018. By Brian Nelson, CFA After earning my MBA at the University of Chicago Booth School of Business and training stock and credit analysts from large organizations over the past decade or so, I have heard just about every question (though I admit I am still surprised by many things and remain a very humble student of the markets). I’ve also spent years perfecting the discounted cash flow process for large research organizations such as Morningstar and studied under one of the most famed aggressive growth investors of all time, Richard Driehaus. My knowledge runs the gamut from value through … Read more

Dividend Increases/Decreases for the Week Ending Apr 28

by

Below we provide a list of firms that raised/lowered their dividends during the week ending April 28. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week AmeriGas Partners (APU): now $0.95 per share quarterly dividend, was $0.94. Ameriprise Financial Services, Inc. (AMP): now $0.83 per share quarterly dividend, was $0.75. Ames National Corporation (ATLO): now $0.22 per share quarterly dividend, was $0.21. Apollo Global Management (APO): now $0.49 per share quarterly dividend, was $0.45. Aspen Insurance Holdings (AHL): now $0.24 per share quarterly dividend, was $0.22. Altra Holdings (AIMC): now $0.17 per … Read more

Dividend Increases/Decreases for the Week Ending April 26

by

Below we provide a list of firms that raised their dividends during the week ending April 26. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week ACNB (ACNB): now $0.25 per share quarterly dividend, was $0.23. AGCO (AGCO): now $0.16 per share quarterly dividend, was $0.15. Agree Realty (ADC): now $0.57 per share quarterly dividend, was $0.555. Alliance Resource Partners (ARLP): now $0.535 per share quarterly dividend, was $0.53. Ameriprise Financial (AMP): now $0.97 per share quarterly dividend, was $0.90. AmeriServ Financial (ASRV): now $0.025 per share quarterly dividend, was $0.02. ASML … Read more

Eli Lilly and Vertex Pharma Provide Promising Guidance for 2021

by

Image Shown: An overview of Vertex Pharmaceuticals Inc’s drug pipeline and commercialized drug portfolio. Image Source: Vertex Pharmaceuticals Inc – Fourth Quarter of 2020 IR Earnings Presentation By Callum Turcan Several pharmaceutical and biotech companies showcased the resilience of their business models last year when faced with severe exogenous headwinds created by the coronavirus (‘COVID-19’) pandemic. For broad-based diversified exposure tied to secular growth tailwinds across the largest drug development companies in the world (and their robust pipelines of drugs and therapies), we include the Health Care Select Sector SPDR ETF (XLV) in both the Best Ideas Newsletter and Dividend Growth Newsletter portfolios. We like this broad exposure to the sector, particularly within diversified portfolios. Eli Lilly (LLY) When Eli … Read more

How Do We Use the Valuentum Buying Index?

by

How Do We Use the Valuentum Buying Index (VBI)? By Brian Nelson, CFA   Hi everyone,     Hope you are doing great!  We often receive questions about how we use the Valuentum Buying Index (VBI) rating system, one of the key metrics we use to source ideas for our members, but we think it is equally important to mention up front that the VBI is only one of the many facets of our website and services. For example, if you haven’t checked out the Dividend Cushion ratios on the stocks in your portfolio or the dividend growth product (from individual reports to the newsletter and beyond), surely you are not maximizing your membership! Don’t forget about the Economic Castle rating, … Read more

Earnings Update on European Big Pharma Featuring Novartis, Sanofi, and AstraZeneca

by

The drug industry is a global market with an impressive array of competitors headquartered outside the US. The quest to bring forth novel treatments continues. We continue to focus on the large-cap traditional pharmaceutical companies for their defensive characteristics, and many also pay a generous dividend. By Alexander J. Poulos Novartis Poised to Cycle Through Loss of Patent Exclusivity on Gleevec Shares of European heavyweight Novartis (NVS) jumped sharply after posting first-quarter earnings April 25. Growth in the pharmaceutical segment remains hampered as the company lapses the loss of patent exclusivity of one of its top-selling products Gleevec. We are looking past the patent cliff and remain focused on the growth products currently in Novartis’ lineup. Cosentyx, a treatment for … Read more